Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

Autor: Shah NN; Medical College of Wisconsin, Milwaukee, WI. nishah@mcw.edu., Wang M; MD Anderson Cancer Center, Houston, TX., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY., Patel K; Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Wierda WG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX., Ujjani CS; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford., Zinzani PL; Institute of Hematology 'Seragnoli' University of Bologna, Bologna., Alencar AJ; University of Miami Sylvester Comprehensive Cancer Center, Miami, FL., Ghia P; Universita Vita-Salute San Raffaele, Milano, Italy; IRCCS Ospedale San Raffaele, Milano., Lamanna N; New York-Presbyterian Columbia University Medical Center, New York, NY., Hoffmann MS; Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL., Flinn I; Sarah Cannon Research Institute, Nashville, TN., Gerson JN; Lymphoma Program, Abramson Cancer Center, Philadelphia, PA., Ma S; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL., Coombs CC; University of California Irvine, Irvine, CA., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Fakhri B; Division of Hematology at Stanford University School of Medicine, Stanford, CA., Kim WS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul., Barve MA; Mary Crowley Cancer Research Center, Dallas, TX., Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland., Munir T; Department of Haematology, St. James's University Hospital, Leeds., Thompson MC; Memorial Sloan Kettering Cancer Center, New York, NY., Tsai DE; Loxo@Lilly, Indianapolis, IN., Bao K; Loxo@Lilly, Indianapolis, IN., Cangemi NA; Loxo@Lilly, Indianapolis, IN., Kherani JF; Loxo@Lilly, Indianapolis, IN., Walgren RA; Loxo@Lilly, Indianapolis, IN., Han H; Loxo@Lilly, Indianapolis, IN., Ruppert AS; Eli Lilly and Company, Indianapolis, IN., Brown JR; Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Publikováno v: Haematologica [Haematologica] 2024 Oct 03. Date of Electronic Publication: 2024 Oct 03.

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.

Autor: Wierda WG; The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: wwierda@mdanderson.org., Shah NN; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, WA, Australia., Lewis D; Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, UK., Hoffmann MS; The University of Kansas Cancer Center, Kansas City, KS, USA., Coombs CC; University of California Irvine Health, Chao Family Comprehensive Cancer Center, Orange, CA, USA., Lamanna N; Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA., Ma S; Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA., Munir T; Department of Haematology, St James's University Hospital, Leeds, UK., Wang Y; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, UK., Rhodes JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., McKinney M; Duke Cancer Institute, Durham, NC, USA., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Tam CS; Alfred Hospital and Monash University, Melbourne, Australia., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland., Izutsu K; National Cancer Center Hospital, Tokyo, Japan., Alencar AJ; Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA., Patel MR; Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA., Seymour JF; Alfred Hospital and Monash University, Melbourne, Australia., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Thompson PA; Alfred Hospital and Monash University, Melbourne, Australia., Abada PB; Loxo Oncology, Indianapolis, IN, USA., Ho C; Loxo Oncology, Indianapolis, IN, USA., McNeely SC; Loxo Oncology, Indianapolis, IN, USA., Marella N; Loxo Oncology, Indianapolis, IN, USA., Nguyen B; Loxo Oncology, Indianapolis, IN, USA., Wang C; Eli Lilly, Indianapolis, IN, USA., Ruppert AS; Eli Lilly, Indianapolis, IN, USA., Nair B; Loxo Oncology, Indianapolis, IN, USA., Liu H; Loxo Oncology, Indianapolis, IN, USA., Tsai DE; Loxo Oncology, Indianapolis, IN, USA., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2024 Sep; Vol. 11 (9), pp. e682-e692. Date of Electronic Publication: 2024 Jul 18.

Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.

Autor: Stanchina MD; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Montoya S; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Danilov AV; Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Castillo JJ; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Alencar AJ; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Chavez JC; Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Cheah CY; Division of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.; Linear Clinical Research, Nedlands, Western Australia, Australia., Chiattone C; Hematology and Oncology Discipline, Hospital Samaritano-Higienópolis, São Paulo, Brazil., Wang Y; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA., Thompson M; Leukaemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ghia P; Division of Experimental Oncology, IRCSS Ospedale San Raffaele, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Taylor J; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA., Alderuccio JP; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. jalderuccio@med.miami.edu.

Publikováno v: Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2024 Dec; Vol. 21 (12), pp. 867-887. Date of Electronic Publication: 2024 Nov 01.